Applying the 2005 Canadian Hypertension Education Program recommendations: 5. Therapy for patients with hypertension and diabetes mellitus

CMAJ. Canadian Medical Association Journal

Volumn 173, Issue 10, 2005, Pages 1154-1157

  Tobe, Sheldon ^a   McAlister, Finlay A ^b   Leiter, Lawrence ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN A1C; HYDROCHLOROTHIAZIDE; INSULIN; METOPROLOL; NIFEDIPINE; ORAL ANTIDIABETIC AGENT; TRANDOLAPRIL; VERAPAMIL;

ADULT; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; BRADYCARDIA; CANADA; CASE REPORT; CLINICAL FEATURE; CREATININE CLEARANCE; DISEASE ACTIVITY; DISEASE CONTROL; EPIDEMIOLOGICAL DATA; HEALTH EDUCATION; HEART BLOCK; HUMAN; HYPERTENSION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; REVIEW; TREATMENT OUTCOME;

EID: 27744443081     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.050188     Document Type: Review

References (4)

1. Khan NA, McAlister FA, Lewanczuk RZ, et al. The 2005 Canadian Hypertension Education Program recommendations for the management of hyper-tension: part II - therapy. Can J Cardiol 2005;21:657-72.
2. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703-13.
3. Ravid M, Brosh D, Ravid-Safran D, et al. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 1998;158:998-1004.
4. Hansson L, Zanchetti A. The Hypertension Optimal Treatment (HOT) Study: 24-month data on blood pressure and tolerability. Blood Press 1997;6:313-7.